Immuneering Corporation reported financial results for the quarter ended June 30, 2026. The company ended Q2 with $182.7 million in cash and marketable securities, providing an anticipated runway into 2029. Research and development expenses increased to $14.0 million from $10.5 million in the prior year period, while general and administrative expenses rose to $5.0 million from $4.3 million. The net loss attributable to common stockholders was $17.3 million, or $0.27 per share, compared to a $14.4 million loss, or $0.40 per share, in the same quarter of 2025. Operationally, Immuneering announced it has dosed the first patient in its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in combination with chemotherapy for first-line pancreatic cancer. The company also highlighted compelling Phase 2a data presented at ASCO showing a 17.3-month median overall survival and appointed Andrew Gengos as Chief Financial Officer. Immuneering Corporation is a late-stage clinical oncology company focused on developing Deep Cyclic Inhibitors to treat RAS, RAF, and MAPK-driven cancers.

Immuneering Corporation appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026. Mr. Gengos, formerly of Terns Pharmaceuticals, will succeed Mallory Morales in the role of principal financial officer, while Ms. Morales will continue as principal accounting officer. His employment agreement includes a $530,000 annual base salary, a 40% target discretionary annual performance bonus, and a contingent 650,000 share option grant. Immuneering Corporation is a biopharmaceutical company focused on developing therapeutic solutions for oncology and neurodegenerative diseases.

Immuneering Corporation announced updated Phase 2a clinical trial data for atebimetinib in combination with mGnP in first-line pancreatic cancer patients, reporting a median overall survival of 17.3 months compared to 8.5 months for the standard of care. The 320 mg dose group demonstrated a median progression-free survival of 8.3 months, an overall response rate of 36%, and a disease control rate of 82%. The company also expects to dose the first patient in a pivotal Phase 3 trial in mid-2026.